EWTX

Edgewise Therapeutics (EWTX)

Edgewise Therapeutics Inc

일자:

규정 관련뉴스

텍스트 검색:

정렬 기준:

규정 외 뉴스

검색 관련기사 보기:NASDAQ:EWTX

1 2 3 4 5 6 7 8 다음 >>

일자	시간	출처	헤드라인	심볼	기업
2024/09/25	09:25	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:EWTX	Edgewise Therapeutics Inc
2024/09/25	09:24	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:EWTX	Edgewise Therapeutics Inc
2024/09/21	05:46	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:EWTX	Edgewise Therapeutics Inc
2024/09/21	05:29	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:EWTX	Edgewise Therapeutics Inc
2024/09/19	20:00	Business Wire	Edgewise Therapeutics Announces Positive Top-Line Data from Phase 1 Trial in Healthy Subjects and Phase 2 CIRRUS-HCM Trial in Patients with Obstructive Hypertrophic Cardiomyopathy (HCM)	NASDAQ:EWTX	Edgewise Therapeutics Inc
2024/09/18	05:01	Business Wire	Edgewise Therapeutics to Host Webcast Event to Discuss Top-Line Data from Phase 1 trial in Healthy Subjects and Phase 2 CIRRUS-HCM Trial in Patients with Obstructive Hypertrophic Cardiomyopathy (HCM) on Thursday, September 19 at 8:30 am Eastern Time	NASDAQ:EWTX	Edgewise Therapeutics Inc
2024/08/15	05:15	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:EWTX	Edgewise Therapeutics Inc
2024/08/15	05:14	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:EWTX	Edgewise Therapeutics Inc
2024/08/13	06:07	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:EWTX	Edgewise Therapeutics Inc
2024/08/08	21:06	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:EWTX	Edgewise Therapeutics Inc
2024/08/08	21:00	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:EWTX	Edgewise Therapeutics Inc
2024/08/08	21:00	Business Wire	Edgewise Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights	NASDAQ:EWTX	Edgewise Therapeutics Inc
2024/06/13	08:23	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:EWTX	Edgewise Therapeutics Inc
2024/05/10	22:10	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:EWTX	Edgewise Therapeutics Inc
2024/05/10	22:07	Edgar (US Regulatory)	Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers	NASDAQ:EWTX	Edgewise Therapeutics Inc
2024/05/10	21:00	Business Wire	Edgewise Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference on May 15, 2024	NASDAQ:EWTX	Edgewise Therapeutics Inc
2024/05/09	22:21	Edgar (US Regulatory)	Form S-8 - Securities to be offered to employees in employee benefit plans	NASDAQ:EWTX	Edgewise Therapeutics Inc
2024/05/09	21:06	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:EWTX	Edgewise Therapeutics Inc
2024/05/09	21:00	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:EWTX	Edgewise Therapeutics Inc
2024/05/09	21:00	Business Wire	Edgewise Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights	NASDAQ:EWTX	Edgewise Therapeutics Inc
2024/05/07	22:16	Edgar (US Regulatory)	Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material	NASDAQ:EWTX	Edgewise Therapeutics Inc
2024/05/07	22:14	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:EWTX	Edgewise Therapeutics Inc
2024/05/07	21:00	Business Wire	Edgewise Therapeutics Appoints Arlene Morris to its Board of Directors	NASDAQ:EWTX	Edgewise Therapeutics Inc
2024/05/06	21:00	Business Wire	Edgewise Therapeutics Doses First Patient in Phase 2 CIRRUS-HCM Trial of EDG-7500 in Obstructive Hypertrophic Cardiomyopathy (HCM)	NASDAQ:EWTX	Edgewise Therapeutics Inc
2024/04/23	21:00	Business Wire	Edgewise Receives European Medicines Agency (EMA) Orphan Drug Designations for Sevasemten (EDG-5506) for the Treatment of Becker and Duchenne Muscular Dystrophies	NASDAQ:EWTX	Edgewise Therapeutics Inc
2024/04/16	05:05	Business Wire	Edgewise Therapeutics Announces Positive Two-Year Topline Results from the ARCH Open Label Trial of Sevasemten (EDG-5506) in Adults with Becker Muscular Dystrophy (Becker)	NASDAQ:EWTX	Edgewise Therapeutics Inc
2024/03/28	21:00	Business Wire	Edgewise Therapeutics Announces Upcoming Podium Presentation at the American College of Cardiology's 2024 Annual Scientific Session	NASDAQ:EWTX	Edgewise Therapeutics Inc
2024/03/27	21:00	Business Wire	Edgewise Therapeutics to Present at the Cantor Virtual Muscular Dystrophy Symposium on April 2, 2024	NASDAQ:EWTX	Edgewise Therapeutics Inc
2024/03/05	22:00	Business Wire	Edgewise Therapeutics to Present at the Leerink Partners Global Biopharma Conference on March 11, 2024	NASDAQ:EWTX	Edgewise Therapeutics Inc
2024/02/28	22:00	Business Wire	Edgewise Therapeutics to Present on EDG-5506 for the Treatment of Becker Muscular Dystrophy at the 2024 MDA Clinical and Scientific Conference	NASDAQ:EWTX	Edgewise Therapeutics Inc